Advitech to Present Recent Data on Wound Healing at the Gordon Research Conference

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announced that Dr Charles Doillon, M.D., Ph.D., Researcher at Centre de Recherche du Centre Hospitalier de l'Université Laval, who is leading Advitech's wound healing program, will be presenting a progress report on the Corporation's IM technological platform for wound management at Gordon Research Conference ("GRC") on Tissue Repair and Regeneration at Colby-Sawyer College, New London, NH, on Thursday June 18th, 2009.

For over 75 years, GRC's meetings have been recognized as the world's premier scientific conferences, where leading investigators from around the globe discuss their latest work and future challenges. Advitech's presentation was accepted after a scientific peer reviewed evaluation.

"During this meeting, scientists around the world will have the possibility to comment new data released on the IM fraction and its wound healing properties. Also, we expect to use this meeting to introduce the IM fraction to pharmaceutical companies" said Dr Doillon.

The progress report will present updated information which, in Advitech's opinion, demonstrates that the IM fraction reduces scar formation and prevents hypertrophic scarring. This bioactivity appears to be associated with the presence of growth factors and peptides with immune modulatory properties as well as antimicrobial activities.

In 2008, Advitech initiated an extensive R&D wound healing program to characterize specific fractions and to obtain toxicological data through in vitro and in vivo studies. Advitech intends to take advantage of the unique bioactive properties of the IM fraction to launch a cosmeceutical product line by the end of 2009.

A recipient of scientific and medical awards, Dr Doillon is currently a full professor (Dept. Surgery) at Laval University, Quebec City, and researcher at the Research Center of the Centre Hospitalier de l'Universite Laval (CHUL). Dr Doillon has authored and co-authored several scientific publications and communications in the fields of wound healing and collagen remodeling, and was a pioneer by demonstrating a correlation between collagen fiber distribution and biomechanics in wound tissues.

According to Epsicom Business Intelligence Ltd., the global wound care market totalled $7.2 billion in 2006, with a 10% growth rate. The market growth is fueled by the population ageing, the increased incidence of diabetes as well as the technological advancement and the introduction of more efficient and cost-effective therapies compared to conventional treatments.

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex®for the treatment of mild-to-moderate psoriasis.

Advitech has initiated an innovative wound healing research program to develop new applications for both its XP-828L and IM technological platforms.

This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.